Market Overview:
The global antidiuretic hormone (ADH) market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of diabetes and other chronic diseases, rising geriatric population, and technological advancements in ADH therapies. However, the high cost of treatment is likely to restrain the growth of this market during the forecast period. Based on type, the global ADH market is segmented into intravenous injection, intramuscular injection, and subcutaneous injection. The intravenous injection segment is expected to account for a major share of the global ADH market in 2018 owing to its ease of use and better patient compliance as compared to other types of injections. By application, anti-diuretic hormone deficiency accounts for a major share of the global ADH market owing to its high prevalence across different regions worldwide.
 Industry Outlook.svg)
Product Definition:
A hormone that is produced by the pituitary gland and that regulates the amount of water in the body by affecting urine production. Antidiuretic hormone (ADH) is important because it helps to maintain blood pressure and fluid balance in the body.
Intravenous Injection:
Intravenous injection is a medical procedure wherein the drug or medication is administered into the vein of the patient. The IV medications are preferred over oral medications because they bypass gastrointestinal system and reach to the blood stream directly.
Intravenous Injection (IVI) has become an integral part of modern healthcare, it's usage.
Intramuscular Injection:
Intramuscular injection is a method of delivering a drug into the muscle. Intra muscular or intramuscular means that the drug is injected directly into muscle tissue. The most common use of this technique in ADH treatment involves administration of dextrose 5% in water (D5W), which is used to treat low blood sugar (hypoglycemia).
Application Insights:
The anti-diuretic hormone deficiency segment dominated the global market in 2017 and is expected to witness the fastest growth over the forecast period. The rising prevalence of diabetes has led to an increase in cases of ADH deficiency, which results in water retention and electrolyte imbalance, leading to neurological symptoms such as confusion, headache and vision changes.
Vasodilatory shock is another major application for antidiuretic hormones. It is a rare condition characterized by low blood pressure due to a loss of response from the body¢â‚¬â„¢s natural defense mechanisms against hypovolemic conditions such as inadequate fluid intake or increased excretion of urine. Symptoms include pale skin with blue veins at rest, cold sweats at night time along with mental dullness and anxiety if not treated on time.
Regional Analysis:
North America dominated the global market in 2017. The growth is majorly attributed to the presence of key players, such as Pfizer Inc.; Merck & Co., Inc.; and sanofi. These companies are engaged in extensive R&D activities for new product development and approval. Moreover, increasing prevalence of diabetes is also expected to fuel market growth over the forecast period. For instance, according to CDC estimates published in MMWR Weekly on July 27th 2018, there were 29 million adults with diagnosed diabetes in U.S., which represents 7% of population aged 20 years and above (age-adjusted).
Growth Factors:
- Increasing incidence of diabetes: The increasing incidence of diabetes is one of the major growth drivers for the antidiuretic hormone market. Diabetes is a condition that results in high levels of blood sugar and can damage many parts of the body, including the eyes, kidneys, nerves, and heart. People with diabetes are at risk for developing various complications such as nerve damage (neuropathy), kidney disease (nephropathy), and eye problems such as cataracts and glaucoma. Diabetic neuropathy is a common complication caused by nerve damage in people with diabetes. It affects up to 60%–70% of people who have had diabetes for 10 years or more2. Rising geriatric population: The geriatric population is another key factor driving the growth of the antidiuretic hormone market worldwide3. Unmet medical needs: There are several unmet medical needs in this market that offer lucrative opportunities to players4 Increased awareness about ADH therapy: There has been an increase in awareness about ADH therapy among physicians and patients alike5 Technological advancements: Technological advancements have led to better diagnosis rates and treatment options for patients suffering from conditions related to ADH deficiency
Scope Of The Report
Report Attributes
Report Details
Report Title
Antidiuretic Hormone (ADH) Market Research Report
By Type
Intravenous Injection, Intramuscular Injection, Subcutaneous Injection
By Application
Anti-Diuretic Hormone Deficiency, Vasodilatory Shock, Gastrointestinal Bleeding, Ventricular Tachycardia & Fibrillation
By Companies
Novartis, Pfizer, Fresenius Kabi, Par Pharmaceutical, Ferring Pharmaceuticals, Astellas Pharma, Shanghai Soho-Yiming Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Antidiuretic Hormone (ADH) Market Report Segments:
The global Antidiuretic Hormone (ADH) market is segmented on the basis of:
Types
Intravenous Injection, Intramuscular Injection, Subcutaneous Injection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Anti-Diuretic Hormone Deficiency, Vasodilatory Shock, Gastrointestinal Bleeding, Ventricular Tachycardia & Fibrillation
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Pfizer
- Fresenius Kabi
- Par Pharmaceutical
- Ferring Pharmaceuticals
- Astellas Pharma
- Shanghai Soho-Yiming Pharmaceuticals
 Market Overview.svg)
Highlights of The Antidiuretic Hormone (ADH) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Intravenous Injection
- Intramuscular Injection
- Subcutaneous Injection
- By Application:
- Anti-Diuretic Hormone Deficiency
- Vasodilatory Shock
- Gastrointestinal Bleeding
- Ventricular Tachycardia & Fibrillation
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Antidiuretic Hormone (ADH) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Antidiuretic hormone (ADH) is a hormone that helps the body conserve water. It is produced in the hypothalamus and released into the blood stream when it detects a decrease in blood volume. ADH then travels to various parts of the body, including the kidneys, where it increases urine production.
Some of the key players operating in the antidiuretic hormone (adh) market are Novartis, Pfizer, Fresenius Kabi, Par Pharmaceutical, Ferring Pharmaceuticals, Astellas Pharma, Shanghai Soho-Yiming Pharmaceuticals.
The antidiuretic hormone (adh) market is expected to grow at a compound annual growth rate of 5.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Antidiuretic Hormone (ADH) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Antidiuretic Hormone (ADH) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Antidiuretic Hormone (ADH) Market - Supply Chain
4.5. Global Antidiuretic Hormone (ADH) Market Forecast
4.5.1. Antidiuretic Hormone (ADH) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Antidiuretic Hormone (ADH) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Antidiuretic Hormone (ADH) Market Absolute $ Opportunity
5. Global Antidiuretic Hormone (ADH) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Antidiuretic Hormone (ADH) Market Size and Volume Forecast by Type
5.3.1. Intravenous Injection
5.3.2. Intramuscular Injection
5.3.3. Subcutaneous Injection
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Antidiuretic Hormone (ADH) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Antidiuretic Hormone (ADH) Market Size and Volume Forecast by Application
6.3.1. Anti-Diuretic Hormone Deficiency
6.3.2. Vasodilatory Shock
6.3.3. Gastrointestinal Bleeding
6.3.4. Ventricular Tachycardia & Fibrillation
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Antidiuretic Hormone (ADH) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Antidiuretic Hormone (ADH) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Antidiuretic Hormone (ADH) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Antidiuretic Hormone (ADH) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Antidiuretic Hormone (ADH) Demand Share Forecast, 2019-2029
9. North America Antidiuretic Hormone (ADH) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Antidiuretic Hormone (ADH) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Antidiuretic Hormone (ADH) Market Size and Volume Forecast by Application
9.4.1. Anti-Diuretic Hormone Deficiency
9.4.2. Vasodilatory Shock
9.4.3. Gastrointestinal Bleeding
9.4.4. Ventricular Tachycardia & Fibrillation
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Antidiuretic Hormone (ADH) Market Size and Volume Forecast by Type
9.7.1. Intravenous Injection
9.7.2. Intramuscular Injection
9.7.3. Subcutaneous Injection
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Antidiuretic Hormone (ADH) Demand Share Forecast, 2019-2029
10. Latin America Antidiuretic Hormone (ADH) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Antidiuretic Hormone (ADH) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Antidiuretic Hormone (ADH) Market Size and Volume Forecast by Application
10.4.1. Anti-Diuretic Hormone Deficiency
10.4.2. Vasodilatory Shock
10.4.3. Gastrointestinal Bleeding
10.4.4. Ventricular Tachycardia & Fibrillation
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Antidiuretic Hormone (ADH) Market Size and Volume Forecast by Type
10.7.1. Intravenous Injection
10.7.2. Intramuscular Injection
10.7.3. Subcutaneous Injection
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Antidiuretic Hormone (ADH) Demand Share Forecast, 2019-2029
11. Europe Antidiuretic Hormone (ADH) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Antidiuretic Hormone (ADH) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Antidiuretic Hormone (ADH) Market Size and Volume Forecast by Application
11.4.1. Anti-Diuretic Hormone Deficiency
11.4.2. Vasodilatory Shock
11.4.3. Gastrointestinal Bleeding
11.4.4. Ventricular Tachycardia & Fibrillation
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Antidiuretic Hormone (ADH) Market Size and Volume Forecast by Type
11.7.1. Intravenous Injection
11.7.2. Intramuscular Injection
11.7.3. Subcutaneous Injection
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Antidiuretic Hormone (ADH) Demand Share, 2019-2029
12. Asia Pacific Antidiuretic Hormone (ADH) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Antidiuretic Hormone (ADH) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Antidiuretic Hormone (ADH) Market Size and Volume Forecast by Application
12.4.1. Anti-Diuretic Hormone Deficiency
12.4.2. Vasodilatory Shock
12.4.3. Gastrointestinal Bleeding
12.4.4. Ventricular Tachycardia & Fibrillation
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Antidiuretic Hormone (ADH) Market Size and Volume Forecast by Type
12.7.1. Intravenous Injection
12.7.2. Intramuscular Injection
12.7.3. Subcutaneous Injection
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Antidiuretic Hormone (ADH) Demand Share, 2019-2029
13. Middle East & Africa Antidiuretic Hormone (ADH) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Antidiuretic Hormone (ADH) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Antidiuretic Hormone (ADH) Market Size and Volume Forecast by Application
13.4.1. Anti-Diuretic Hormone Deficiency
13.4.2. Vasodilatory Shock
13.4.3. Gastrointestinal Bleeding
13.4.4. Ventricular Tachycardia & Fibrillation
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Antidiuretic Hormone (ADH) Market Size and Volume Forecast by Type
13.7.1. Intravenous Injection
13.7.2. Intramuscular Injection
13.7.3. Subcutaneous Injection
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Antidiuretic Hormone (ADH) Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Antidiuretic Hormone (ADH) Market: Market Share Analysis
14.2. Antidiuretic Hormone (ADH) Distributors and Customers
14.3. Antidiuretic Hormone (ADH) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novartis
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Fresenius Kabi
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Par Pharmaceutical
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Ferring Pharmaceuticals
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Astellas Pharma
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Shanghai Soho-Yiming Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
